Pharvaris stock
PHVSNASDAQPharvaris N.V., HealthcareISIN NL00150005Y4
44Score 44 out of 100, Weak
Price and trend
81 / 100
Price history
+31% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 8.0% above it.
Since July 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 64).
The price is 13% below its 52-week high. Largest decline in 6 years: 95% (February 2021 to December 2022).
Chart figures for advanced users
- SMA 50$33.29
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$31.31
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)64
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$23.55
- The lowest closing price of the last twelve months.
- Resistance$38.86
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Pharvaris N.V. belongs to the Biotechnology industry (Switzerland) and, with a market value of $2.38B, is number 112 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 44 out of 100 (Weak): rank 477 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $323.21M, financial debt $860.77K.Stability 73
Weaknesses
- DilutionShare count up 94% since 2020.Capital allocation 18
- Loss-makingLoss of $194.69M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$152.07M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 8 Apr 2027in 146 days
- Last reported
- 12 Nov 2026EPS reported −0.77 (expected −0.81)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −2.81−0.6%
- Revenue
- $1.26M+0.4%
- Earnings per share
- −2.72−0.6%
- Revenue
- $36.59M+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 11 insiders sold, $27.99M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Monges VivianeSale
23 Sept 2026, Board
- Shares
- 11,969
- Price
- $33.05
- Value
- $395,524
- Schikan Johannes Gerardus Christiaan PetrusSale
22 Sept 2026, Board
- Shares
- 800
- Price
- $36.19
- Value
- $28,952
- Nassif David W.Sale
21 Sept 2026, CFO / CLO
- Shares
- 6,000
- Price
- $36.47
- Value
- $218,801
Show 36 more
- Lu PengSale
17 Sept 2026, President
- Shares
- 100,000
- Price
- $35.00
- Value
- $3.5M
- Schikan Johannes Gerardus Christiaan PetrusSale
17 Sept 2026, Board
- Shares
- 200,000
- Price
- $35.00
- Value
- $7M
- Bjork ElisabethSale
17 Sept 2026, Board
- Shares
- 52,500
- Price
- $37.89
- Value
- $1.99M
- Glassman RobertSale
17 Sept 2026, Board
- Shares
- 14,493
- Price
- $38.56
- Value
- $558,812
- Lesage AnneSale
17 Sept 2026, Chief Early Development
- Shares
- 20,000
- Price
- $38.27
- Value
- $765,466
- Abele Stefan AndreasSale
15 Sept 2026, Chief Technical Ops Officer
- Shares
- 46,400
- Price
- $38.17
- Value
- $1.77M
- Glassman RobertSale
15 Sept 2026, Board
- Shares
- 8,667
- Price
- $38.27
- Value
- $331,716
- Souverijns WimSale
15 Sept 2026, Chief Commercial Officer
- Shares
- 6,090
- Price
- $38.99
- Value
- $237,449
- Souverijns WimSale
14 Sept 2026, Chief Commercial Officer
- Shares
- 20,000
- Price
- $39.31
- Value
- $786,126
- Modig BerndtSale
14 Sept 2026, Chief Executive Officer
- Shares
- 2,291
- Price
- $39.40
- Value
- $90,276
- Lu PengSale
11 Sept 2026, President
- Shares
- 15,000
- Price
- $40.13
- Value
- $601,947
- Lesage AnneSale
10 Sept 2026, Chief Early Development
- Shares
- 30,000
- Price
- $38.30
- Value
- $1.15M
- Glassman RobertSale
9 Sept 2026, Board
- Shares
- 8,000
- Price
- $37.55
- Value
- $300,396
- Lu PengSale
8 Sept 2026, President
- Shares
- 15,000
- Price
- $40.68
- Value
- $610,134
- Modig BerndtSale
14 Aug 2026, Chief Executive Officer
- Shares
- 2,292
- Price
- $34.77
- Value
- $79,686
- Modig BerndtSale
13 Jul 2026, Chief Executive Officer
- Shares
- 2,292
- Price
- $34.97
- Value
- $80,154
- Schikan Johannes Gerardus Christiaan PetrusSale
30 Jun 2026, Board
- Shares
- 30,712
- Price
- $35.49
- Value
- $1.09M
- Lesage AnneSale
30 Jun 2026, Chief Early Development
- Shares
- 58,575
- Price
- $35.48
- Value
- $2.08M
- Schikan Johannes Gerardus Christiaan PetrusSale
29 Jun 2026, Board
- Shares
- 6,888
- Price
- $35.05
- Value
- $241,447
- Lesage AnneSale
29 Jun 2026, Chief Early Development
- Shares
- 17,597
- Price
- $35.06
- Value
- $616,925
- Schikan Johannes Gerardus Christiaan PetrusSale
29 Jun 2026, Board
- Shares
- 2,400
- Price
- $35.10
- Value
- $84,250
- Lu PengSale
26 Jun 2026, Chief Medical Officer
- Shares
- 14,700
- Price
- $34.00
- Value
- $499,847
- Lesage AnneSale
25 Jun 2026, Chief Early Development
- Shares
- 4,600
- Price
- $35.12
- Value
- $161,560
- Lu PengSale
25 Jun 2026, Chief Medical Officer
- Shares
- 15,000
- Price
- $34.60
- Value
- $518,985
- Lu PengSale
18 Jun 2026, Chief Medical Officer
- Shares
- 300
- Price
- $34.00
- Value
- $10,200
- Modig BerndtSale
15 Jun 2026, Chief Executive Officer
- Shares
- 2,291
- Price
- $31.07
- Value
- $71,173
- Nijdam AnnaSale
4 Jun 2026, Principal Accounting Officer
- Shares
- 2,670
- Price
- $30.87
- Value
- $82,425
- Nijdam AnnaSale
22 May 2026, Principal Accounting Officer
- Shares
- 5,501
- Price
- $30.74
- Value
- $169,084
- Monges VivianeSale
21 May 2026, Board
- Shares
- 9,667
- Price
- $30.29
- Value
- $292,853
- Nijdam AnnaSale
21 May 2026, Principal Accounting Officer
- Shares
- 1,829
- Price
- $30.60
- Value
- $55,971
- Nassif David W.Sale
21 May 2026, CFO / CLO
- Shares
- 10,000
- Price
- $30.31
- Value
- $303,076
- Bjork ElisabethSale
20 May 2026, Board
- Shares
- 10,000
- Price
- $29.32
- Value
- $293,166
- Modig BerndtSale
18 May 2026, Chief Executive Officer
- Shares
- 2,292
- Price
- $29.22
- Value
- $66,977
- Glassman RobertSale
15 May 2026, Board
- Shares
- 10,000
- Price
- $29.82
- Value
- $298,245
- Abele Stefan AndreasSale
15 May 2026, Chief Technical Ops Officer
- Shares
- 8,748
- Price
- $29.82
- Value
- $260,864
- Souverijns WimSale
15 May 2026, Chief Commercial Officer
- Shares
- 10,000
- Price
- $29.92
- Value
- $299,163
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Pharvaris
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Bavarian NordicBAVA.CO $2.7B71
- Arcus BiosciencesRCUS $2.56B30
- Beam TherapeuticsBEAM $2.49B38
- NewAmsterdam PharmaNAMS $2.4B35
- Zealand PharmaZEAL.CO $2.37B59
- Replimune GroupREPL $2.31B42
- Lakefront BiotherapeuticsLKFT $2.26B74
- Celldex TherapeuticsCLDX $2.24B34
ETFs that hold Pharvaris
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.17% | 0.40% | €580.62M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.15% | 0.35% | €1.25B |
| UBS MSCI EMU Small Cap UCITS ETF EUR disUEFD | 0.14% | 0.28% | €630.46M |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.06% | 0.23% | €321.86M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.05% | 0.30% | €3.45B |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.02% | 0.34% | €16.96M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.